Pulmonary arterial hypertension (PAH) is a rare and serious condition that affects the blood vessels of the lungs and can significantly limit daily activities and quality of life. Some patients with PAH use inhaled iloprost, a medication that requires several inhalations per day, which can be difficult to maintain over time. Oral selexipag is an alternative treatment that may reduce treatment burden and improve adherence.
The PROMISE study aims to evaluate how switching from inhaled iloprost to oral selexipag affects patients' quality of life, satisfaction with treatment, and adherence in real-world clinical practice. Patient-reported outcome questionnaires will be used to understand patients' perceptions of symptoms, daily functioning, and overall improvement after the transition.
Adult patients with PAH who are receiving inhaled iloprost and whose physicians decide to switch treatment to oral selexipag will be followed over time. A comparison group of patients who continue using inhaled iloprost will also be observed. The study does not involve any experimental treatment or changes to routine clinical care. All medications are prescribed as part of standard medical practice.
The results of this study may help improve understanding of the patient experience during treatment transitions in PAH and support more patient-centered treatment decisions.
Adults aged 18 years or older.
Confirmed diagnosis of pulmonary arterial hypertension (PAH, Group 1) by right heart catheterization.
Current treatment with inhaled iloprost as part of routine clinical care.
Clinical decision by the treating physician to transition from inhaled iloprost to oral selexipag.
Significant cognitive impairment or sensory deficits that prevent completion of study questionnaires.
Unstable or decompensated comorbid conditions that may interfere with treatment adherence or study participation.
Refusal or inability to provide informed consent.